Not available
Quote | Denali Therapeutics Inc. (NASDAQ:DNLI)
Last: | $21.30 |
---|---|
Change Percent: | 0.0% |
Open: | $21.97 |
Close: | $21.30 |
High: | $22.27 |
Low: | $21.29 |
Volume: | 491,640 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Denali Therapeutics Inc. (NASDAQ:DNLI)
2024-06-15 15:37:28 ET The market for medicines to treat amyotrophic lateral sclerosis (ALS) in major markets is projected to more than surge to $1.28B in 2029 from $317M in 2019, representing a CAGR of 15%.... Read the full article on Seeking Alpha For further details see: ...
2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...
Message Board Posts | Denali Therapeutics Inc. (NASDAQ:DNLI)
Subject | By | Source | When |
---|---|---|---|
DNLI on Seeking Alpha | conix | investorshub | 01/16/2023 7:09:13 PM |
Up big, why? | seward | investorshub | 09/28/2022 2:49:10 PM |
Up 5 pts AH news or random bid ? | seward | investorshub | 08/15/2021 1:13:47 PM |
Add 55.55 Been holding for 100+, flipping small shares | seward | investorshub | 05/04/2021 2:11:17 PM |
More flipping. Filled for one share at 57 this | seward | investorshub | 03/09/2021 2:51:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Denali Therapeutics Inc. Company Name:
DNLI Stock Symbol:
NASDAQ Market:
Denali Therapeutics Inc. Website:
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potentia...
2024-05-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal sto...